Home  |  Corporate Info  |  R & D  |  Products  |  Investor Relations  |  Careers at Hemispherx  


 

Hemispherx Biopharma Press Release for
Wednesday, December 02, 2009



Hemispherx Biopharma Announces Investor Conference Call

Philadelphia, PA, Wednesday, December 02, 2009: Hemispherx Biopharma, Inc. (NYSE Amex: HEB) announces an investor update by teleconference on Thursday, December 3, 2009 at 10:00am EST. The update will cover regulatory status of its platform technology (Ampligen®, Alferon-N®, Alferon® LDO), strategic partnering and other matters, followed by a Q and A period.

To access the conference call:
U.S. Callers: 800-348-5860
International Callers: 973-528-0008
Conference Entry Code: 27781

This call will be webcast via the Company’s website at: http://www.hemispherx.net.

A digital replay of the call will be available until December 18th by calling:
U.S. Callers: 800-332-6854
International Callers: 973-528-0005
Conference Entry Code: 27781

About Hemispherx Biopharma
Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx’s flagship products include Alferon N Injection® (FDA approved for a category of sexually transmitted diseases) and the experimental therapeutics Ampligen® Oragens®, and Alferon LDO. Ampligen® and Oragens® represent experimental RNA nucleic acids being developed for globally important debilitating diseases and disorders of the immune system. Hemispherx’s platform technology includes large and small agent components for potential treatment of various severely debilitating and life threatening diseases. Hemispherx has in excess of 50 patents comprising its core intellectual property estate and a fully commercialized product (Alferon N Injection®). The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products. For more information please visit www.hemispherx.net.


Contact:
Hemispherx Biopharma, Inc.,
Dianne Will, Investor Relations
(518) 398-6222, Fax: (518) 398-6369

HEB's Web Site: www.hemispherx.net


Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the completion of the NDA filing process with Ampligen® and the receipt of a Complete Response Letter from the FDA do not imply that the Company will be able to successfully comply with any or all of the requirements requested in that Letter or that the product will ever be approved for commercial sale. In addition, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company’s filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the Company (including Ampligen®, Alferon® LDO and Oragens®) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company’s judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Clinical trials for other potential indications of the approved biologic Alferon N Injection® do not imply that the product will ever be specifically approved commercially for these other treatment indications.